GLP-1类似物在肥胖症临床治疗中的应用

Current Opinion in Endocrine and Metabolic Research Pub Date : 2022-08-01 DOI:10.1016/j.coemr.2022.100360

Rachel Agius , Claudia Coelho , Barbara McGowan

{"title":"GLP-1类似物在肥胖症临床治疗中的应用","authors":"Rachel Agius , Claudia Coelho , Barbara McGowan","doi":"10.1016/j.coemr.2022.100360","DOIUrl":null,"url":null,"abstract":"<div>Obesity is a chronic disease requiring chronic management. Anti-obesity medication for the treatment of obesity includes the glucagon-like peptide-1 (GLP-1) agonists liraglutide and semaglutide. This review will discuss the results of weight loss clinical trials for these agents, in addition to anorectic gut hormone analogue combinations and co-agonist drugs targeting gut hormone receptors, as well as the implications for the clinical management of obesity.</div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"25 ","pages":"Article 100360"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"GLP-1 analogues in clinical management of obesity\",\"authors\":\"Rachel Agius , Claudia Coelho , Barbara McGowan\",\"doi\":\"10.1016/j.coemr.2022.100360\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>Obesity is a chronic disease requiring chronic management. Anti-obesity medication for the treatment of obesity includes the glucagon-like peptide-1 (GLP-1) agonists liraglutide and semaglutide. This review will discuss the results of weight loss clinical trials for these agents, in addition to anorectic gut hormone analogue combinations and co-agonist drugs targeting gut hormone receptors, as well as the implications for the clinical management of obesity.</div>\",\"PeriodicalId\":52218,\"journal\":{\"name\":\"Current Opinion in Endocrine and Metabolic Research\",\"volume\":\"25 \",\"pages\":\"Article 100360\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Endocrine and Metabolic Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S245196502200045X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Endocrine and Metabolic Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S245196502200045X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

肥胖是一种需要长期控制的慢性疾病。用于治疗肥胖的抗肥胖药物包括胰高血糖素样肽-1 (GLP-1)激动剂利拉鲁肽和西马鲁肽。本综述将讨论这些药物的减肥临床试验结果，以及厌食肠道激素类似物组合和针对肠道激素受体的协同激动剂药物，以及对肥胖临床管理的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

GLP-1 analogues in clinical management of obesity

Obesity is a chronic disease requiring chronic management. Anti-obesity medication for the treatment of obesity includes the glucagon-like peptide-1 (GLP-1) agonists liraglutide and semaglutide. This review will discuss the results of weight loss clinical trials for these agents, in addition to anorectic gut hormone analogue combinations and co-agonist drugs targeting gut hormone receptors, as well as the implications for the clinical management of obesity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Opinion in Endocrine and Metabolic Research Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

4.10

自引率

0.00%

发文量